Clinical Trial Update: Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing dopamine enhancement of fear extinction learning in post-traumatic stress disorder has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Stress Disorder, Post Traumatic | Phase 4 | Status: COMPLETED | Results posted: 2019-06-25